November #96 : Guiding Light? - by Liz Highleyman

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Reversal of Fortune

Worlds Apart

There She Is...

Trial and Trial Again

Closing the Gap

African Bandstand

Pharma Adapts to ADAP

Stone Cold Killing

Hyper Activists

Who Gives a Fund?

Talkin' Turkey


Can You Hear Me Now?

RETROPOZ: It Happened in November

Shout Out

Say What?

Paris is for HIVers

World on a (Shoe)string

Paris Scope: 6 Quick Picks from IAS

Bone UP

Bone Appétit

Guiding Light?

Quick Study: HPV and HAART

Heeling Power

Warning Signs

Drama Queen

Can Your Inner Ham

Burn, BABY, Burn


Sunshine State


Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

November 2003

Guiding Light?

by Liz Highleyman

In July a panel of AIDS experts released 96 pages of revised federal HIV treatment guidelines.

If you’re just starting treatment...

The old guide sized up each med for mixing and matching; now, “the cocktails, not the individual drugs, are evaluated,” explains POZ medical advisor David Gelman, MD. The feds recommend two combos: non-nuke Sustiva + 3TC + (AZT or d4T or Viread), and protease inhibitor Kaletra + 2 nukes (3TC, AZT or d4T). This contradicts British HIV Association guidelines, which reject starting with too-toxic d4T (see “London Calling,” POZ, September 2003).

Now emphasizing individualized therapy, the guidelines OK triple-nuke combo 3TC + Ziagen + (AZT or d4T) only if your viral load is under 100,000, and nix Sustiva or a ddI + d4T combo if you’re preggers or planning to be.

If you’ve been around the treatment block...
What’s new for oldies? A detailed definition of “treatment failure” along with advice on picking new meds after a combo flops:
1. Try switching combos or adding drugs from new classes (like entry inhibitors) to perk up a pooped regimen.
2. Use resistance testing to guide new drug choices.
3. Don’t use blood drug-level monitoring (“therapeutic drug monitoring”)—it’s not clear it helps.
4. Add a PI booster to ratchet up the power of your combo. “Avoid STIs,” the guidelines say, echoing past versions.

If you think this all sounds old hat...
Join the club. “Guidelines by their very nature are conservative— behind the curve of clinical knowledge once they come out,” Gelman says, noting that newcomers PI Reyataz and nuke Emtriva are barely mentioned. What they do offer is backup for docs to make your insurance cover that slightly off-beat combo.

“Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents” can be yours. Call: 800.448.0440. Write: AIDS INFO, P.O. Box 6303, Rockville, MD 20849. Surf:

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.